Abstract
Previous studies addressing functional aspects of nuclear factor κB (NF-κB) activation in normal and transformed keratinocytes revealed complex and seemingly contradictory roles of this transcription factor in this cell type. In normal skin, NF-κB signaling seems to inhibit squamous cell carcinoma development whereas, in squamous cell carcinoma themselves, deregulated NF-κB expression and/or signaling is frequently observed. To further investigate this paradox, we focused on NF-κB activation as it relates to the transformed phenotype of immortalized but nontumorigenic human keratinocytes (HaCaT cells). We observed that NF-κB activity contributed to survival and growth of cultured HaCaT keratinocytes as shown by use of pharmacologic NF-κB inhibitors, BNA interference, and inducible overexpression of a dominant interfering IκB construct. NF-κB activation was largely provided through interaction with extracellular matrix components because preventing cell attachment by forced suspension culture markedly reduced NFκB signaling associated with cell death (anoikis); conversely, anoikis was partially reversed by NF-κB activation induced either by tumor necrosis factor-α treatment or by overexpressing the NF-κB p65 subunit in HaCaT cells. Furthermore, overexpression of NF-κBp65 in HaCaT cells induced colony formation in soft agar and tumorigenicity in nude mice. In summary, as opposed to normal keratinocytes, immortalized HaCaT keratinocytes provide a cellular context in which deregulated NF-κB signaling supports multiple malignant traits in vitro and in vivo.
Original language | English |
---|---|
Pages (from-to) | 5209-5215 |
Number of pages | 7 |
Journal | Cancer Research |
Volume | 66 |
Issue number | 10 |
DOIs | |
State | Published - May 15 2006 |
Keywords
- Animals
- Carcinoma, Squamous Cell/metabolism
- Cell Adhesion/physiology
- Cell Line
- Cell Survival/physiology
- Cell Transformation, Neoplastic/metabolism
- Extracellular Matrix/pathology
- Humans
- Keratinocytes/metabolism
- Mice
- Mice, Nude
- NF-kappa B/antagonists & inhibitors
- Signal Transduction
- Transcription Factor RelA/biosynthesis
- Tumor Necrosis Factor-alpha/pharmacology